Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Neoplasms, Hormone-Dependent
  • Neoplastic Cells, Circulating
  • Prostatic Neoplasms
  • Receptors, Androgen

abstract

  • Acquired resistance to first-line hormonal therapy in prostate cancer is heterogeneous in the extent of AR pathway reactivation. Measurement of pre- and posttreatment AR signaling within CTCs may help target such treatments to patients most likely to respond to second-line therapies.

publication date

  • November 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3508523

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-12-0222

PubMed ID

  • 23093251

Additional Document Info

start page

  • 995

end page

  • 1003

volume

  • 2

number

  • 11